Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs RVT-1502 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Ligand Pharmaceuticals
- 15 Aug 2016 According to Ligand Pharmaceuticals Media Release results of two phase I stuidies (phase Ia and phase Ib) were published in the Journal of Diabetes, Obesity and Metabolism.
- 15 Aug 2016 Results published in the Ligand Pharmaceuticals Media Release
- 04 May 2016 Results presented at the Levine-Riggs Diabetes Research Symposium 2016, according to a Ligand Pharmaceuticals media release.